VISION
Cutting Edge Research,
Real World Impact
CBT focuses on the root cause of drug resistance and immune evasion for cancer. We target the tough stuff, the types of cancers that make people lose hope, the kind that comes back.
We have discovered promising treatments for recurrent drug resistant adult and childhood cancers showing tumor regression and potential cures.
OUR FOCUS
We succeed where other therapies fail by focusing on the root cause of disease
1.2m
New Cancer Cases for the Top 10 Cancers Alone in US
400k
Of These Will Recur
5%
Survival for Recurrent, Drug Resistant Cancers
$150k
Average Cost of Cancer Treatments per Year
DRUG
CBT300
Preclinical Phase
A First-in-Class biologic for recurrent and drug resistant cancers where there are no effective treatments, CBT300 is a platform monotherapy that is non-toxic, inexpensive and potentially life saving. Alone or in combination with Standard of Care, CBT300 reverses the drug resistance and immune evasion that leads to mortality.
Dr. Donald Davidson's approach is radically different from large pharmaceutical and other biotech companies by beginning research where current therapies fail to gain a thorough understanding of the underlying mechanisms leading to drug resistance.
THE SCIENCE
Reversing Drug Resistance and Immune Suppression in Cancer
THE SCIENCE
Advancements in Dr. Davidson’s lab at CBT have led to the discovery of a survival mechanism leading to drug resistance and immune system evasion. As a result, he designed several novel, first-in-class inhibitors that remove this survival pathway and allow for immune system activation.
Preclinical studies in several drug resistant cancers with lead biologic CBT300 have shown no toxicity, increased survival, significant tumor regression, immune invasion and disease elimination for several cancers including breast, brain (pediatric/adult), lung, colon, melanoma, ovarian and renal cancers.
EFFICACY
65%
Tumor Regression
CBT300 has shown efficacy in multiple cancer models alone or in combination with low dosing chemotherapy. In one 28-day 4T1 combination study tumors regressed by 65% with 100% survival in combination animals. Histological analysis of study tumors for immune infiltration validated an excellent influx of immune cells in the CBT300 treated tumors with very few viable tumor cells compared to standard of care or control tumors. This study and others support efficacy for both drug resistant reversal and immunotherapeutic response.
EFFECTIVE
88%
Survival in Drug Resistant MBC Models
Head to head testing of CBT against a highly used immunotherapy resulted in superior survival in Melanoma, Lung, Renal cancers and an equal survival in MBC though the CBT300 arms showed no off target or toxicity. In addition to in vivo testing, CBT has excellent spheroid data for near complete regression alone in several patient derived spheroids for DIPG, GBM, mTNBC, Ovarian, and Lung.
CBT300 Survival vs Anti-PD-1
Melanoma
P<0.05
Lung
P<0.01
Renal
P<0.05
Breast (TNBC)
P<0.0001
0%
63%
0%
0%
75%
37%
0%
88%
63%
0%
88%
88%
Control
CBT300
Anti-PD-1
CBT optimizes partner relationships for ongoing testing in viral disease
Based on preclinical success with increased survival in COVID-19, EBOLA and Tamiflu Resistant Influenza A, CBT300 continues to be tested as a lifesaving antiviral therapy through the US Army research division.
Collaboration with Dr. Candece Gladson, Cleveland Clinic, is expanding CBT’s evidentiary support in brain cancer for tumor-brain barrier studies.
Colorado State University will perform a pilot Glioblastoma dog study with CBT300 as a monotherapy.
STATUS
Lead therapy CBT300 has one target used in multiple diseases
Lead biologic therapy, CBT300 will revolutionize the treatment landscape for recurrent, drug and immune resistant cancers, late-stage viruses and neurodegenerative diseases that rely on the same novel survival pathway. Upon completion of our drug scale up and rodent toxicity study, we will secure our Investigative New Drug (IND) approval with the FDA to begin Phase I clinical trials, beginning in Metastatic Breast Cancer with brain metastases.
DISCOVERY
PRECLINICAL
PHASE I
PHASE II
MARKET
UNDISCLOSED DISEASE 2
DISCOVERY
UNDISCLOSED DISEASE 1
PRECLINICAL
PARKINSON'S
DISCOVERY
ALZHEIMER'S
PRECLINICAL
EBOLA
READY FOR PHASE I
INFLUENZA A
READY FOR PHASE I
COVID 19
READY FOR PHASE I
PROSTATE CANCER
PRECLINICAL
COLON CANCER
PRECLINICAL
BRAIN CANCER | PEDIATRIC
PRECLINICAL
BRAIN CANCER | ADULT
PRECLINICAL
OVARIAN CANCER
PRECLINICAL
MELANOMA CANCER
READY FOR PHASE I
LUNG CANCER
READY FOR PHASE I
RENAL CANCER
READY FOR PHASE I
2027
BREAST CANCER
READY FOR PHASE I
1
Non-Toxic Therapy
16
Disease Development Pathways
300m
US Total Available Market
$200b
Potential Revenue in US
NEWS
April 8, 2024
Creative BioTherapeutics competed in the final investment pitch competition SAC25 with the Seattle Angels coming in 2nd. Competing against 114 other companies, CBT was one of the final 6 companies competing for an SPV Seattle Angel investment from the participating 35 angels. CBT has been in Due Diligence with a select team of investors that have outstanding experience in pharma, biotech, business and technology. CBT is currently working with several of the SAC investors for direct investments.
Apr 7-10, 2024
Poster Presentation, American Association of Cancer Research; Extracellular GRP78 Inhibition Reverses Drug and Immune Resistance in Cancer Cells, American Association for Cancer Research, San Diego, CA
Mar 27-28, 2024
Poster Presentation, Glioblastoma Drug Development Summit; Reversing Drug & Immune Resistance in Adult & Pediatric Gliomas by Inhibiting Extracellular GRP78, Glioblastoma Drug Development Summit, Boston, MA.
Dec 5-9, 2023
Poster Presentation, San Antonio Breast Cancer Symposium; Innovative Metastatic Breast Cancer Therapy, CBT300, Reverses Drug and Immune Resistance, San Antonio Breast Cancer Symposium
November 8, 2023
Creative Biotherapeutics places first in the Brown Rudnick Women’s Health & Wellness Pitch Event, in New York City November 8, 2023. Creative BioTherapeutics was one of 10 companies invited to pitch at this elite event focusing on women's health initiatives. The panel of judges included Marissa Fayer, medtech executive, innovator, entrepreneur and philanthropist. She is the CEO/Founder of nonprofit HERhealth EQ, CEO of DeepLook Medical and US Partner at Goddess Gaia Ventures. Also panelists Matthew Jones, Founder/CEO of Everbeat, Samantha Bader, Principal at Morgan Health and Renato Merino, Latina Emerging Fund Manager. CBT won an annual membership to Scroobious PIP Platform whose mission is to increase diversity in the startup ecosystem by teaching founders how to create investable pitch materials.
Gurnee, Illinois, April 2022-Creative BioTherapeutics LLC (CBT) was granted a National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase II award for $990,000 in support of the clinical development of its Novel Anti-viral Technology. This anti-viral technology can revert the COVID-19 infected and stressed lung cells to a non-infected, normal state. The mechanism of action of CBT’s lead anti-viral therapy blocks all variants of concern for COVID-19 since it protects normal cells from virus infection. This emerging, pre-clinical therapy has also been shown to be effective for multiple viruses including Ebola and Influenza.
Creative BioTherapeutics (CBT) was awarded and successfully completed a Phase I NSF SBIR grant in 2021. The Phase I grant was awarded to only 1% of applicants (20,000 applicants) and the Phase II grant is awarded to less than 50% of Phase I recipients that apply. This award is highly prestigious with only 1,200 awarded over the past 20 years. The review process is extremely rigorous involving full scientific, business, and financial reviews in order to ensure that the awarded company has the team and resources to move aggressively toward the market. CBT is awarded this very elite and prestigious grant to continue to move the lead anti-viral drug toward clinical trials and commercialization with a goal of market entry in 2024. After receiving the Phase II award, CBT is now eligible to receive up to $500,000 in additional matching funds with qualifying third-party investment or sales.
“This Phase II grant is an exciting opportunity for CBT to more quickly move our therapy toward commercialization to provide hope and potential return to health for patients with late-stage COVID-19 or other viral diseases that otherwise could lead to death. As a company, we target difficult to treat diseases where there are few available options. We are very excited to continue our work with the NSF” says Dr. Anita Davidson, Co-Founder/President.
About the National Science Foundation's Small Business Programs: America’s Seed Fund powered by NSF awards $200 million annually to startups and small businesses, transforming scientific discovery into products and services with commercial and societal impact. Startups working across almost all areas of science and technology can receive up to $1.75 million to support research and development (R&D), helping de-risk technology for commercial success. America’s Seed Fund is congressionally mandated through the Small Business Innovation Research (SBIR) program. The NSF is an independent federal agency with a budget of about $8.1 billion that supports fundamental research and education across all fields of science and engineering. For more information, visit seedfund.nsf.gov.
Gurnee, Illinois, January 2021-Creative BioTherapeutics LLC was awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $255,700 to conduct research and development (R&D) work on Development of a Novel Therapy for the Treatment of COVID-19.
Creative BioTherapeutics (CBT) has discovered that a viral infection stresses the body similarly to the way that comorbidities such as cancer create stress. COVID-19 infection causes the patient to deteriorate more quickly as a result of these conditions by placing enormous stress on the cells making them more susceptible to virus infection and COVID-19 related death. To solve these issues, CBT has created a novel and ground breaking therapy to reduce cellular stress, block virus infection and increase survival for late-stage COVID-19 patients.
“NSF is proud to support the technology of the future by thinking beyond incremental developments and funding the most creative, impactful ideas across all markets and areas of science and engineering,” said Andrea Belz, Division Director of the Division of Industrial Innovation and Partnerships at NSF. “With the support of our research funds, any deep technology startup or small business can guide basic science into meaningful solutions that address tremendous needs.”
“When we identified the way that viruses infect and compared this information to how our cancer therapies work, we realized that we had an exciting opportunity to reduce the negative impact from COVID-19 disease and save lives. This therapy could stop future pandemics by understanding how the virus infects the body.”
— Donald Davidson, PhD, Co-Founder/CEO CBT
Once a small business is awarded a Phase I SBIR/STTR grant (up to $256,000), it becomes eligible to apply for a Phase II grant (up to $1,000,000). Small businesses with Phase II grants are eligible to receive up to $500,000 in additional matching funds with qualifying third-party investment or sales.
Startups or entrepreneurs who submit a three-page Project Pitch will know within three weeks if they meet the program’s objectives to support innovative technologies that show promise of commercial and/or societal impact and involve a level of technical risk. Small businesses with innovative science and technology solutions, and commercial potential are encouraged to apply. All proposals submitted to the NSF SBIR/STTR program, also known as America’s Seed Fund powered by NSF, undergo a rigorous merit-based review process. To learn more about America’s Seed Fund powered by NSF, visit: https://seedfund.nsf.gov/
About the National Science Foundation's Small Business Programs: America’s Seed Fund powered by NSF awards $200 million annually to startups and small businesses, transforming scientific discovery into products and services with commercial and societal impact. Startups working across almost all areas of science and technology can receive up to $1.75 million to support research and development (R&D), helping de-risk technology for commercial success. America’s Seed Fund is congressionally mandated through the Small Business Innovation Research (SBIR) program. The NSF is an independent federal agency with a budget of about $8.1 billion that supports fundamental research and education across all fields of science and engineering.
Our Board of Directors
OUR TEAM
Decentralized for Optimal Strength and Efficiency
Currently, CBT incorporates a streamlined business model, optimizing efficiency through effective utilization of top tier contract partners. In addition to our research, manufacturing and regulatory contract partners, we have engaged a wide range of technical advisors and operational business partners to support our ongoing business and drug development. As we move closer to clinical trials and subsequently the market with CBT300, we will expand our business platform as appropriate following our outlined for business expansion to ensure long term research and development success.
CRO's
OUR TEAM
Want to make your mark in changing cancer treatment?
Drug resistant cancers are incurable. For the 400,000 patients in the US with recurrent cancers, highly toxic therapies are the standard of care with few extending overall survival. With the billions of dollars spend annually in cancer research and development, Patients continue to be left behind.
In contrast, CBT CEO/Founder has designed and is developing a First-in-Class biologic, CBT300, as a breakthrough, non-toxic therapy that reverses drug resistance, engages the immune system and eradicates tumors.
METASTATIC BREAST CANCER
287k
New Invasive Cases/Year in US
A leading cause of death in women, 131,700 cases recur from drug resistance with a 5-year survival rate of < 25% and annual mortality of >40,000 for the last 30 years.
GLIOBLASTOMA
24k
Primary Brain Tumors in US
300,000 people are living with secondary brain tumors annually in the US due to metastasis from other recurrent, drug resistant cancers. Glioblastoma has a near 100% mortality within 18 months from diagnosis.
PEDIATRIC BRAIN CANCER
300-400
Cases/Year
Brain cancer is a leading cause of childhood death with DIPG consistently the most deadly. These children are not expected to live past 1 year with no current effective treatments.
ALZHEIMER'S
6.7m
Alzheimer’s Patients in US
Alzheimer’s Disease is incurable with a prolonged loss of productive life and societal burden with protracted disease lasting through the last 20 years of life.